An updated review of anti-Ro52 (TRIM21) antibodies impact in connective tissue diseases clinical management.
Fiche publication
Date publication
décembre 2021
Journal
Autoimmunity reviews
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DE CARVALHO BITTENCOURT Marcelo
Tous les auteurs :
Decker P, Moulinet T, Pontille F, Cravat M, Bittencourt MC, Jaussaud R
Lien Pubmed
Résumé
Anti-Ro52 (or anti-TRIM21) antibodies are part of the family of anti-Ro/SSA antibodies, historically markers of Sjögren syndrome and systemic lupus erythematosus. Anti-Ro52 antibodies represent one the most frequently encountered autoantibodies in patients with connective tissue disease (primary Sjögren syndrome, systemic lupus erythematosus, systemic sclerosis and idiopathic inflammatory myopathies). Because of their lack of specificity and detection in patients with non-autoimmune disorders, the usefulness of anti-Ro52 testing in connective tissue diseases is still matter of debate among clinicians and immunologists. Autoantibodies are mainly diagnostic markers for autoimmune diseases but some of them can also be directly involved in the generation of tissue damage. Over the past decade several authors reported associations of anti-Ro52 antibodies with some clinical features - especially interstitial lung disease - and survival in patients with connective tissue diseases. There is also a growing evidence of the role of anti-Ro52 antibodies in the pathogenesis of connective tissue diseases. In this review, we comprehensively discuss the clinical associations of anti-Ro52 antibodies in the different connective tissue diseases and the recent advances on their potential role in the inflammatory response.
Mots clés
Anti-Ro52 antibodies, Anti-TRIM21 antibodies, Connective tissue disease, Ro52, TRIM21
Référence
Autoimmun Rev. 2021 Dec 9;:103013